NASDAQ:MBRX
Moleculin Biotech Inc Stock News
$4.76
-0.0200 (-0.418%)
At Close: May 10, 2024
Oppenheimer Sticks to Its Buy Rating for Moleculin Biotech (MBRX) - Markets
04:54pm, Thursday, 02'nd Jul 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRX – Research Report),
Moleculin Provides Update on Annamycin Clinical Development
11:30am, Thursday, 02'nd Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
09:50pm, Wednesday, 01'st Jul 2020
In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.
New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model
11:30am, Wednesday, 01'st Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Moleculin Biotech, Inc. (NASDAQ:
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
12:35pm, Monday, 29'th Jun 2020
NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
11:30am, Thursday, 25'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
12:49pm, Tuesday, 23'rd Jun 2020
NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.
Moleculin to Present at the Life Sciences Investor Forum
11:30am, Tuesday, 23'rd Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today annou
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
12:00am, Tuesday, 23'rd Jun 2020
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com
WPD Pharmaceuticals : Licensor Announces Confirmatory in Vitro Analysis of WP1122 | MarketScreener
11:01am, Monday, 22'nd Jun 2020Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
03:30pm, Wednesday, 17'th Jun 2020
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Announces Confirmatory In Vitro Analysis of WP1122
11:30am, Tuesday, 16'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at Maxim Group
03:38am, Wednesday, 10'th Jun 2020
Equities research analysts at Maxim Group began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Tuesday, TipRanks reports. The brokerage set a “buy” rating and a $3.00
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
11:30am, Thursday, 04'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted request
